Protein degradation and drug discovery by Monte Rosa Therapeutics
Monte Rosa Therapeutics pledges support for LGBTQ employees with focus on authentic workplace culture
Monte Rosa Therapeutics has reaffirmed its dedication to fostering an inclusive work environment where employees do not have to choose between professional advancement and personal authenticity. ...
Monte Rosa Therapeutics advances NEK7-targeted MRT-8102 for cardiovascular disease inflammation
Monte Rosa Therapeutics introduces MRT-8102, a NEK7-directed molecular glue degrader, as a novel strategy in combating cardiovascular disease driven by inflammation. The company’s Chief Medical ...
Monte Rosa Therapeutics advances molecular glue degrader strategy at Jefferies Healthcare Conference
Monte Rosa Therapeutics provided updates on its clinical pipeline and ongoing progress in molecular glue degrader programs during a fireside chat at the Jefferies Global Healthcare Conference in ...
Monte Rosa Therapeutics spotlights molecular glue degraders in treating undruggable proteins
Monte Rosa Therapeutics draws attention to a recent Bloomberg feature exploring the potential of molecular glue degraders for targeting disease-driving proteins previously considered undruggable. ...
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development
Monte Rosa Therapeutics has been recognized as a Disruptive Pioneer by IDEA Pharma in the 2026 Innovation and Invention Index, an annual assessment honoring companies driving groundbreaking ...
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar
Monte Rosa Therapeutics will present its latest research on the versatility of molecular glue degraders during an upcoming Endpoints webinar. The session, featuring Georg Petzold and Chao Quan, ...
Monte Rosa Therapeutics unveils preclinical data on targeting undruggable CCNE1 in solid tumors
Monte Rosa Therapeutics has presented preclinical data at AACR26 regarding its CCNE1-directed molecular glue degrader, aimed at treating CCNE1-amplified solid tumors. The approach suggests a new ...
Monte Rosa Therapeutics CEO to join AACR2026 panel on proximity-induced therapies
Monte Rosa Therapeutics will participate in the AACR2026 conference, with CEO Markus Warmuth set to join a panel of leading biopharma executives focused on proximity-induced therapies. This move ...
Monte Rosa Therapeutics urges new pathways for the next generation of scientists
Monte Rosa Therapeutics asserts that the future of research hinges on inviting individuals to participate early in the scientific process. The company commemorates Women’s History Month by ...
Monte Rosa Therapeutics CEO unveils pipeline progress at TD Cowen Health Care Conference
Monte Rosa Therapeutics CEO Markus Warmuth delivers an update on the company pipeline at the TD Cowen Health Care Conference. Warmuth outlines recent progress and clinical data, focusing on ...
Monte Rosa Therapeutics advances MRT-2359 into Phase 2 trial targeting AR mutations in mCRPC
Monte Rosa Therapeutics moves forward with plans to initiate a new Phase 2 study of MRT-2359 in combination with a second-generation androgen receptor (AR) inhibitor for patients with metastatic ...
Monte Rosa Therapeutics finds novel molecular glue degrader
Monte Rosa Therapeutics has identified a groundbreaking molecular glue degrader that operates through a novel mechanism involving cereblon degradation. This discovery emerged from an extensive ...
